Author Archives: Warren Woessner

OSI v. Apotex – Christmas in October!

Posted on October 11, 2019 by Warren Woessner

In OSI v. Apotex, Appeal no. 2018-1925 (Fed. Cir., October 4, 2019), the panel reversed the PTAB and found that the method of treatment claims in U.S. Pat. No. 6,900,221 were not obvious over a primary reference taken with each … Continue reading →

Posted in Obviousness, Section 103 | Tagged , | Leave a comment

Athena’s “Questionable” Petition for Cert.

Posted on October 8, 2019 by Warren Woessner

On October 1st, Athena filed a petition for a writ of certiorari to the Supreme Court following the Fed. Cir.’s fractured denial for its petition for rehearing en banc in Amgen v. Mayo. The original request for rehearing en banc … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

Senate Subcommittee on IP Holds Hearings on SWOT of STRONGER Bill

Posted on September 16, 2019 by Warren Woessner

This bill has been introduced into both houses of Congress in a bipartisan effort to curb the reach of inter partes review (IPR) proceedings and the broad four-factor analysis for injunctive relief set forth by the Supreme Court in eBay … Continue reading →

Posted in AIA Patent Reform, Inter Partes Review | Tagged , , | Leave a comment

INO v. Praxair – Method-by-Selection Claims Fail Mayo/Alice Test

Posted on September 3, 2019 by Warren Woessner

In Ino Therapeutics LLC v. Praxair Distrib., Inc., Appeal no.2018-1019 (Fed. Cir., August 27, 2019) a divided Fed. Cir. panel comprising Judges Dyk and Prost, Newman dissenting affirmed a district court decision that a number of INO’s patent claims were … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment